Vistogard® is being distributed by BTG Pharmaceuticals as of July 1, 2023. For more details please click here.

Vistogard® (uridine triacetate) fights toxicity so you can continue fighting your cancer 1-3, 21-23

Vistogard® is the first and only antidote to treat 5-FU or capecitabine toxicity 1, 2, 19

  • 130 of 135 (96%) patients in clinical trials survived severe 5-FU or capecitabine toxicity1 1,2
  • 98% of patients survived when treated with Vistogard® within 96 hours of ending their 5-FU or capecitabine chemotherapy 1, 2
  • One-third of study patients continued chemotherapy within a month after treatment with
    Vistogard® 1, 2

*Survival was 96% among all patients treated with Vistogard® for either early-onset severe toxicity or overdose †16% survival was shown in historical case reports of 5-FU overdose 1, 2, 19

Vistogard® is proven safe and tolerable for patients 1, 2, 19

  • The most common side effects from Vistogard® use in 135 patients enrolled in clinical studies were:
    • Vomiting (10% of patients)
    • Nausea (5% of patients)
    • Diarrhea (3% of patients)
  • The effects of Vistogard® don’t depend on patient’s gender or age
  • Of the 135 patients in clinical studies with Vistogard®, 30% were 65 years of age or older and 11% were 75 years of age or older
  • In the clinical studies, one patient receiving Vistogard® had serious nausea and vomiting
  • Two patients (1.4% of those in clinical trials) discontinued Vistogard® due to side effects related to treatment

You are now leaving the patient site.

The section you selected contains information intended for U.S. healthcare professionals only.
Please certify that you are a U.S. healthcare professional by clicking the link below.